Skip to main content

Table 3 Patient-reported improvement in individual symptoms (PP population; N: A = 60, B = 64, C = 56)1

From: Efficacy and safety of 0.05% micellar nano-particulate (MNP) cyclosporine ophthalmic emulsion in the treatment of moderate-to-severe keratoconjunctivitis sicca: a 12-week, multicenter, randomized, active-controlled trial

Eye Symptom

Group

Baseline (SD)

At 12 Wks (SD)

Difference (SD)

P Value 12

P Value 23

Blurred Vision

A

2.1 (1.2)

0.5 (0.6)

-1.6 (1.2)

0.0095

0.2712

B

1.8 (1.2)

0.5 (0.8)

-1.3 (1.2)

0.1215

-

C

1.7 (1.2)

0.7 (0.8)

-1.5 (1.2)

-

-

Dryness

A

3.0 (1.1)

0.9 (0.9)

-2.2 (1.4)

< 0.0001

0.0281

B

3.0 (1.1)

1.3 (0.7)

-1.6 (1.3)

0.0082

-

C

2.5 (1.0)

1.5 (0.8)

-1.0 (1.3)

-

-

Itching

A

2.3 (1.2)

0.5 (0.7)

-1.8 (1.5)

0.0137

0.3903

B

2.6 (1.0)

0.9 (1.0)

-1.7 (1.1)

0.0310

-

C

2.1 (1.1)

0.8 (0.7)

-1.3 (1.0)

-

-

Photosensitivity

A

2.5 (1.3)

0.6 (0.6)

-1.9 (1.4)

0.0012

0.0179

B

2.4 (1.1)

1.0 (1.0)

-1.3 (1.2)

0.2295

-

C

2.0 (1.2)

0.9 (0.7)

-1.1 (1.1)

-

-

Pain/Soreness

A

2.2 (1.2)

0.3 (0.5)

-1.9 (1.1)

0.0351

0.1171

B

2.2 (1.2)

0.6 (0.9)

-1.5 (1.2)

0.5748

-

C

2.2 (1.2)

0.6 (0.6)

-1.4 (1.1)

-

-

Sandy/Gritty

A

2.6 (1.1)

0.7 (0.6)

-2.0 (1.4)

0.0014

0.0086

B

2.4 (1.2)

1.1 (1.0)

-1.3 (1.2)

0.3702

-

C

2.3 (1.2)

1.2 (0.7)

-1.1 (1.3)

-

-

Stinging/Burning

A

2.6 (1.2)

0.6 (0.7)

-2.0 (1.3)

0.0010

0.0493

B

2.4 (1.4)

1.0 (1.0)

-1.5 (1.4)

0.1485

-

C

2.5 (1.3)

1.1 (0.7)

-1.2 (1.2)

-

-

  1. [1] Each eye scored separately
  2. [2] Wilcoxon’s rank sum test: groups A and B vs. group C
  3. [3] Wilcoxon’s rank sum test: group A vs. group B